JAK2 and Splenomegaly: A number of JAK2 inhibitors have been under clinical trials for MPNs, and only the JAK1/JAK2 inhibitor ruxolitinib has been in clinical use in general practice for PMF or PV mainly to reduce splenomegaly and various symptoms and possibly to improve survival of these patients [8].